Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on February 14, 2017. The filing pertains to the scheduling of the Company's 2017 Annual Meeting of Stockholders and the establishment of the record date for shareholder nominations.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural report regarding corporate governance and shareholder meetings.
Material Changes
There are no material financial changes reported in this document. The primary event is the Board of Directors' approval of the record date for the 2017 Annual Meeting.
Guidance, Outlook, and Corporate Actions
- Annual Meeting: The 2017 Annual Meeting of Stockholders is scheduled to be held on or about April 10, 2017. The final date and time will be announced in the upcoming proxy statement.
- Record Date: The record date for stockholders entitled to receive notice and vote at the Annual Meeting is March 15, 2017.
- Shareholder Proposals: Proposals must be received by the Company on or prior to March 2, 2017, at the principal executive offices in Carmiel, Israel.
- Proxy Statement: The Company plans to file a proxy statement with the SEC and mail it to stockholders. This document will contain important information regarding the meeting.
Key Facts for Investor Verification
- Verify the final date and time of the Annual Meeting once the proxy statement is filed.
- Confirm stock ownership status as of the close of business on March 15, 2017, to ensure voting rights.
- Note the March 2, 2017 deadline for submitting shareholder proposals.
- Review the upcoming proxy statement for details on director nominations and executive compensation.